Previous 10 | Next 10 |
Heron finally received FDA approval for Zynrelef but it came with a surprisingly narrow label. The company believes it can secure a broad label with additional studies but the narrow label will likely impact Zynrelef's growth trajectory. The CINV franchise is expected to start to ...
Pacira BioSciences (PCRX) announces that the United States Patent and Trademark Office ((USPTO)) has issued a "Notice of Allowance" for U.S. Patent Application Serial Number 17/156,400 related to pain medicine EXPAREL (bupivacaine liposome injectable suspension).The allowed app...
PARSIPPANY, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice o...
PARSIPPANY, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 RBC Capital Markets Global Healthcare Conference at 10:20 AM ET on Tuesday, May 18, 2021. Live audio of the virtual event can be accessed by visiti...
Pacira BioSciences reported earnings last week, and the company missed on its EPS estimate while beating its revenue estimate. The company has seen tremendous earnings and revenue growth in recent years and it appears as if they will going forward. Short sellers have established a...
PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposo...
Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Conference Call May 4, 2021 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chief Executive Officer and Chairman Charlie Reinhart - Chief Financial Officer Conference Call Participants David Amsellem - Pipe...
Image source: The Motley Fool. Pacira BioSciences, Inc. (NASDAQ: PCRX) Q1 2021 Earnings Call May 4, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript
Pacira BioSciences (PCRX): Q1 Non-GAAP EPS of $0.53 misses by $0.10; GAAP EPS of $0.23 misses by $0.02.Revenue of $119.03M (+12.6% Y/Y) beats by $0.14M.Press Release For further details see: Pacira BioSciences EPS misses by $0.10, beats on revenue
-- EXPAREL average daily sales at 115% of the prior year first quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management ...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...